Literature DB >> 24099884

Treatment adherence in bipolar I and schizoaffective disorder, bipolar type.

A Murru1, I Pacchiarotti, B L Amann, A M A Nivoli, E Vieta, F Colom.   

Abstract

BACKGROUND: Poor adherence rates in Bipolar Disorder type I (BDI) and Schizoaffective Disorder, bipolar type (SAD) may be high This study was aimed at comparing the clinical correlates of adherence to treatment and the course of illness in BDI and SAD patients.
METHODS: 75 SAD and 150 BDI DSM-IV outpatients were included. Adherence was assessed on the basis of patients' and care-givers' reports and serum levels, when available. Socio-demographic, clinical and treatment variables were collected and compared between diagnostic subsamples and then between goodly and poorly adherent patients. Multiple logistic regressions were performed, controlling for diagnostic subsample differences, to identify correlates of adherence in BDI and SAD groups.
RESULTS: Poor adherence was highly prevalent both in BDI (32%) and in SAD patients (44%), with no significant differences between diagnostic categories. Presence of psychotic symptoms (p=0.029), higher number of manic relapses (p<0.001), comorbidity with personality disorders (p=0.002), and lithium therapy (p=0.003) were associated with poor adherence to treatment. Diagnostic subgroup analyses showed different predictive models, with the BDI poorly adherent subsample being more likely to include comorbid personality and manic recurrences and the SAD poorly adherent subsample being less clinically predictable. LIMITATIONS: The cross-sectional nature of the study limits de capacity to ascertain the direction of the relationship between certain variables.
CONCLUSIONS: Rates of poor adherence to oral treatments are similar in SAD and BDI. BDI patients with comorbid personality and substance use disorders are likely to be poorly adherent. Treatment adherence may be more difficult to predict in SAD patients.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adherence to treatment; Bipolar disorder; Schizoaffective disorder

Mesh:

Substances:

Year:  2013        PMID: 24099884     DOI: 10.1016/j.jad.2013.08.026

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  18 in total

Review 1.  Medication Adherence in Patients with Bipolar Disorder: A Comprehensive Review.

Authors:  Jennifer B Levin; Anna Krivenko; Molly Howland; Rebecca Schlachet; Martha Sajatovic
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

Review 2.  Treatment of Bipolar Disorder in a Lifetime Perspective: Is Lithium Still the Best Choice?

Authors:  Gabriele Sani; Giulio Perugi; Leonardo Tondo
Journal:  Clin Drug Investig       Date:  2017-08       Impact factor: 2.859

Review 3.  Antipsychotic Management of Schizoaffective Disorder: A Review.

Authors:  Jean-Pierre Lindenmayer; Amandeep Kaur
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

4.  Modifiable and non-modifiable factors associated with functional impairment during the inter-episodic periods of bipolar disorder.

Authors:  Andrea Murru; Isabella Pacchiarotti; Norma Verdolini; Maria Reinares; Carla Torrent; Pierre-Alexis Geoffroy; Frank Bellivier; Pierre-Michel Llorca; Eduard Vieta; Ludovic Samalin
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-05-22       Impact factor: 5.270

5.  Personality disorder symptom severity predicts onset of mood episodes and conversion to bipolar I disorder in individuals with bipolar spectrum disorder.

Authors:  Tommy H Ng; Taylor A Burke; Jonathan P Stange; Patricia D Walshaw; Rachel B Weiss; Snezana Urosevic; Lyn Y Abramson; Lauren B Alloy
Journal:  J Abnorm Psychol       Date:  2017-04

Review 6.  Medication nonadherence in bipolar disorder: a narrative review.

Authors:  Ibrahim Jawad; Stuart Watson; Peter M Haddad; Peter S Talbot; R Hamish McAllister-Williams
Journal:  Ther Adv Psychopharmacol       Date:  2018-10-16

7.  Saliva testing as a means to monitor therapeutic lithium levels in patients with psychiatric disorders: Identification of clinical and environmental covariates, and their incorporation into a prediction model.

Authors:  Georgia M Parkin; Michael J McCarthy; Soe H Thein; Hillary L Piccerillo; Nisha Warikoo; Douglas A Granger; Elizabeth A Thomas
Journal:  Bipolar Disord       Date:  2021-09-24       Impact factor: 5.345

8.  Symptom severity, self-reported adherence, and electronic pill monitoring in poorly adherent patients with bipolar disorder.

Authors:  Martha Sajatovic; Jennifer B Levin; Johnny Sams; Kristin A Cassidy; Kouri Akagi; Michelle E Aebi; Luis F Ramirez; Steven A Safren; Curtis Tatsuoka
Journal:  Bipolar Disord       Date:  2015-09       Impact factor: 6.744

Review 9.  Allostasis as a conceptual framework linking bipolar disorder and addiction.

Authors:  Mauro Pettorruso; Luisa De Risio; Marco Di Nicola; Giovanni Martinotti; Gianluigi Conte; Luigi Janiri
Journal:  Front Psychiatry       Date:  2014-12-03       Impact factor: 4.157

10.  Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder.

Authors:  Dong-Jing Fu; Ibrahim Turkoz; R Bruce Simonson; David Walling; Nina Schooler; Jean-Pierre Lindenmayer; Carla Canuso; Larry Alphs
Journal:  J Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.